Archives of Gynecology and Obstetrics

, Volume 275, Issue 6, pp 433–438 | Cite as

Efficacy of Yasmin in premenstrual symptoms

  • Surasak Taneepanichskul
  • Unnop Jaisamrarn
  • Vorapong Phupong
Original Article



To evaluate the effect of oral contraception formulation with drospirenone (Yasmin) on premenstrual symptoms.

Materials and methods

An open-label non-comparative clinical trial was conducted. One hundred women who desired oral contraception for at least 6 months were recruited. The subjects received a blister pack which contained 21 tablets of 3 mg drospirenone/30 μg ethinyl estradiol for the first four cycles (1 cycle = 28 days). Cycle-5 and -6 blister packs were dispensed during the next visit in cycle 4. The subjects were evaluated on menstruation-related symptoms by using the women’s health assessment questionnaire (WHAQ) at baseline and at each follow-up visit for three phases of their menstrual cycle. The measured outcome was the mean score changes from baseline to cycle 6 of WHAQ categories.


Of the total 100 subjects, 92 (92%) completed the study. At the premenstrual phase, a significant decrease was seen from baseline to cycle 6 in the mean WHAQ scores for impaired concentration, water retention, negative effect, increased appetite, feeling of well-being and undesirable hair change. At the menstrual phase, a significant decrease was seen from baseline to cycle 6 regarding the mean WHAQ scores for impaired concentration, negative effect, feeling of well-being, and undesirable hair change. At the postmenstrual phase, significant changes were consistently observed regarding the feeling of well-being and undesirable hair change.


Oral contraception formulation with drospirenone (Yasmin) has an ameliorating effect on premenstrual symptoms. This oral contraception may have a role in women who are looking forward to use contraception and also suffer from premenstrual symptoms.


Oral contraception Drospirenone Premenstrual symptoms WHAQ score 


  1. 1.
    Anonymous (1998) An open-label, multicenter, noncomparative safety and efficacy study of Mircette, a low-dose estrogen-progestin oral contraceptive. The Mircette Study Group. Am J Obstet Gynecol 179:S2–S8CrossRefGoogle Scholar
  2. 2.
    Apter D, Borsos A, Baumgartner W, Melis GB, Vexiau-Robert D, Colligs-Hakert A, Palmer M, Kelly S (2003) Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms. Eur J Contracept Reprod Health Care 8:37–51PubMedGoogle Scholar
  3. 3.
    Barnhart KT, Freeman EW, Sondheimer SJ (1995) A clinician’s guide to the premenstrual syndrome. Med Clin North Am 79:1457–1472PubMedGoogle Scholar
  4. 4.
    Boerrigter PJ, Ellman H, Dolker M (1999) International clinical experience with a new low-dose, monophasic oral contraceptive containing levonorgestrel 100 microg and ethinyl estradiol 20 microg. Clin Ther 21:118–127PubMedCrossRefGoogle Scholar
  5. 5.
    Borenstein J, Yu HT, Wade S, Chiou CF, Rapkin A (2003) Effect of an oral contraceptive containing ethinyl estradiol and drospirenone on premenstrual symptomatology and health-related quality of life. J Reprod Med 48:79–85PubMedGoogle Scholar
  6. 6.
    Brown C, Ling F, Wan J (2002) A new monophasic oral contraceptive containing drospirenone. Effect on premenstrual symptoms. J Reprod Med 47:14–22PubMedGoogle Scholar
  7. 7.
    Daugherly JE (1998) Treatment strategies for premenstrual syndrome. Am Fam Physician 58:183–192Google Scholar
  8. 8.
    Dell DL (2004) Premenstrual syndrome, premenstrual dysphoric disorder, and premenstrual exacerbation of another disorder. Clin Obstet Gynecol 47:568–575PubMedCrossRefGoogle Scholar
  9. 9.
    Endrikat J, Muller U, Dusterberg B (1997) A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 30 micrograms ethinylestradiol/75 micrograms gestodene, with respect to efficacy, cycle control, and tolerance. Contraception 55:131–137PubMedCrossRefGoogle Scholar
  10. 10.
    Eriksson E, Sundblad C, Lisjo P, Modigh K, Andersch B (1992) Serum levels of androgens are higher in women with premenstrual irritability and dysphoria than in controls. Psychoneuroendocrinology 17:195–204PubMedCrossRefGoogle Scholar
  11. 11.
    Foidart JM, Wuttke W, Bouw GM, Gerlinger C, Heithecker R (2000) A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur J Contracept Reprod Health Care 5:124–134PubMedCrossRefGoogle Scholar
  12. 12.
    Logue CM, Moos RH (1986) Perimenstrual symptoms: prevalence and risk factors. Psychosom Med 48:388–414PubMedGoogle Scholar
  13. 13.
    Moline ML (1993) Pharmacologic strategies for managing premenstrual syndrome. Clin Pharm 12:181–196PubMedGoogle Scholar
  14. 14.
    Moos RH (1991) Menstrual distress questionnaire manual. Western Psychological Service, Los AngelesGoogle Scholar
  15. 15.
    Muhn P, Fuhrmann U, Fritzemeier KH, Krattenmacher R, Schillinger E (1995) Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Ann N Y Acad Sci 761:311–335PubMedCrossRefGoogle Scholar
  16. 16.
    Oelkers W (2000) Drospirenone—a new progestogen with antimineralocorticoid activity, resembling natural progesterone. Eur J Contracept Reprod Health Care 5(Suppl3):17–24PubMedGoogle Scholar
  17. 17.
    Oelkers W (2004) Drospirenone, a progestogen with antimineralocorticoid properties: a short review. Mol Cell Endocrinol 217:255–261PubMedCrossRefGoogle Scholar
  18. 18.
    Parsey KS, Pong A (2000) An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen. Contraception 61:105–111PubMedCrossRefGoogle Scholar
  19. 19.
    Severino SK, Moline ML (1989) Premenstrual syndrome: a clinician’s guide. Guilford press, New YorkGoogle Scholar
  20. 20.
    Sveindottir H, Backstrom T (2000) Prevalence of menstrual cycle symptom cyclicity and premenstrual dysphoric disorder in a random sample of women using and not using oral contraceptives. Acta Obstet Gynecol Scand 79:405–413PubMedCrossRefGoogle Scholar
  21. 21.
    World Health Organization (WHO) (1996). Improving access to quality care in family planning. Medical eligibility criteria for contraceptive use methods. World Health Organization, GenevaGoogle Scholar
  22. 22.
    Yonkers KA, Brown C, Pearlstein TB, Foegh M, Sampson-Landers C, Rapkin A (2005) Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol 106:492–501Google Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Surasak Taneepanichskul
    • 1
  • Unnop Jaisamrarn
    • 1
  • Vorapong Phupong
    • 1
  1. 1.Department of Obstetrics and Gynecology, Faculty of MedicineChulalongkorn UniversityBangkokThailand

Personalised recommendations